Source: https://x.com/agingroy/status/2039680847700205949?s=20
3 Likes
How some people sleep only four hours a night and still feel great
Who are these hidden superheroes?
Natural short sleep isn’t a mindset, a habit or a product of willpower. It’s a biological variant.
Over the past two decades, researchers have identified a small cluster of genes that allow some people to sleep far less than average while remaining perfectly healthy.
One of the first clues came from a gene called DEC2, which helps regulate levels of orexin, a brain chemical that promotes wakefulness.
Too little orexin is known to cause narcolepsy; yet natural short sleepers appear to produce more of it, keeping them alert on much less rest.
Orexin is created in the hypothalamus, and promotes alertness, focus and regular sleep cycles - Credit: Getty
When researchers introduced the mutation into mice, they found the animals slept significantly less without showing the cognitive lapses that normally follow sleep deprivation.
Since then, at least seven genes have been linked to this phenomenon. In every case, engineering the human mutation into mice leads to the same result: shorter sleep cycles with no obvious downside.
According to Prof Guy Leschziner, a consultant neurologist and sleep expert, everything we currently know suggests that natural short sleep is entirely genetic.
He rarely sees such people in clinic – partly because it isn’t a disorder, and partly because those who have it often don’t realise they’re unusual.
“Short sleepers don’t assume it’s abnormal in any way until someone close to them points it out,” he says.
“Particularly if there’s a family history, there will be other individuals who sleep with a similar pattern. So for them it’s normal.”
But while natural short sleepers remain a genetic rarity, the science that explains them is accelerating.
Read the full story here: How some people sleep only four hours a night and still feel great | BBC Science Focus Magazine
Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent
April 7, 2026
Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral sclerosis, obesity, hypertension, retinopathy, multiple sclerosis, narcolepsy, hypersomnia and Parkinson’s disease, among others.
source: Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent | BioWorld
Alkermes Launches Phase 3 Brilliance Program for Alixorexton in Narcolepsy
In recent news, Alkermes has initiated the phase 3 Brilliance clinical program evaluating alixorexton, an investigational oral orexin 2 receptor (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2).¹ The program includes three randomized, double-blind, placebo-controlled trials—Brilliance NT1 (Studies 302 [NCT07455383] and 304) and Brilliance NT2 (Study 303; NCT07502443)—each designed to assess efficacy, safety, and dosing strategies over a 12-week treatment period.
Phase 3 Program Design and Endpoints
The Brilliance studies will evaluate both once-daily and split-dose regimens of alixorexton across global populations. In NT1, each study is expected to enroll approximately 150 patients, while the NT2 trial will include approximately 180 participants.
“The initiation of the phase 3 Brilliance Studies program marks an exciting and important milestone for alixorexton. Building on the positive findings observed in our large phase 2 program across both narcolepsy type 1 and type 2, we are entering this pivotal stage with confidence,” Craig Hopkinson, MD, MBChB, Chief Medical Officer and Executive Vice President of Research & Development at Alkermes, said in a statement.1 “We look forward to evaluating alixorexton in both once-daily and split-dose regimens as we seek to optimize efficacy, safety and dosing flexibility in the development of a potential new treatment option for patients and providers.”
Across all studies, the primary endpoint is change from baseline to week 12 in mean sleep latency on the Maintenance of Wakefulness Test (MWT), a standard objective measure of wakefulness. Secondary endpoints include changes in Epworth Sleepiness Scale (ESS) scores, patient-reported outcomes assessing fatigue and cognition, and overall disease severity.2,3
Orexin clinical trials to participate in…
More info: ClinicalTrials.gov
Upcoming trials:
More info: ClinicalTrials.gov
and other studies focused on Orexin 2 receptor agonists: ClinicalTrials.gov
Has anybody gotten hold of and used Orexin A? I tried but failed in ordering lyophilized poweder from the vendors highlighted by RapAdmin (MedChen Express demands a business address and Target Moi requires an internal product code that I cannot access). So that leaves me with Limitless Life nasal spray, shared by Tim, but I´ll first see if I get any response here.
All the better to compete with new robot replacements.
1 Like
No Sleep, and Neuralink… if you can’t beat them, join them 
And then there is a family in Italy that suffers from FFI, or fatal family insomnia. Caused by a genetic mutation, the disorder has such symptoms as paranoia, hallucinations, severe sweating, and rapid weight loss, ultimately leading to delirium and death.
New Yorker writer D.T. Max wrote a book on the subject, 'The Family That Couldn’t Sleep," and fans of Gabriel Garcia Marquez will remember that the inhabitants of Macondo were seized by an “insomnia plague.”
2 Likes
Direct Peptide Replacement: Biotech’s Multi-Billion Dollar Bet on the Master Switch of Wakefulness
The standard of care for narcolepsy has long been a “band-aid” approach, using broad-spectrum stimulants to mask daytime sleepiness without addressing the underlying pathology. This landscape shifted dramatically in early 2026. The biotech sector is now pivoting toward orexin receptor-2 agonists , a new class of small molecules designed to mimic the missing neuropeptides that maintain the human wake-sleep cycle.
Narcolepsy Type 1 (NT1) is primarily an autoimmune-driven deficiency. The immune system destroys a specific cluster of neurons in the hypothalamus responsible for producing orexin (hypocretin). Without this “master switch,” patients suffer from fragmented sleep, sudden muscle collapse (cataplexy), and cognitive “brain fog”.
The clinical results for the front-runner, Takeda’s oveporexton (TAK-861), suggest a paradigm shift. Unlike previous attempts that failed due to liver toxicity, oveporexton has cleared Phase 2 trials with a high safety profile, significantly extending wakefulness and reducing cataplexy episodes. The industry’s confidence is reflected in Eli Lilly’s recent $6.3 billion acquisition of Centessa Pharmaceuticals’ pipeline, signaling that orexin agonists are viewed not just as narcolepsy drugs, but as potentially revolutionary “cognitive enhancers” or “clean stimulants” for a variety of neurological conditions.
Actionable Insights
For the longevity-focused community, the emergence of orexin agonists represents a new frontier in neurological optimization. While currently targeted at NT1 and NT2, the “pleiotropic” nature of orexin signaling—affecting attention, mood, and memory—suggests these compounds may eventually be used off-label for age-related cognitive decline or “brain fog” associated with neurodegeneration.
-
Pipeline Monitoring: Keep a close watch on alixorexton (ALKS 2680) and ORX750. These are moving into Phase 3 and have shown efficacy in both narcolepsy types, suggesting they could be more versatile than earlier candidates.
-
The Sleep-Cognition Link: The data reinforces that “wakefulness” is not merely the absence of sleep but a peptide-regulated state required for cognitive vigilance. Optimizing endogenous orexin through lifestyle—or eventually via these agonists—could be a key strategy for maintaining executive function in aging.
-
Precision Stimulants: Unlike caffeine or amphetamines, which have broad cardiovascular impacts, orexin agonists target a specific hypothalamic pathway. This offers a more “surgical” approach to alertness with a lower risk of systemic jitteriness, though insomnia and urinary urgency remain noted side effects.
Source:
- Paper/Article: First orexin agonists address root cause of narcolepsy
- Institutions: Stanford University (USA), Takeda (Japan), Centessa Pharmaceuticals (UK/USA), Alkermes (Ireland/USA), Nxera Pharma (Japan).
- Journal: Nature Biotechnology.
- Impact Evaluation: The impact score of this journal is 33.1 (JIF 2024), evaluated against a typical high-end range of 0–60+ for top general science; therefore, this is an Elite impact journal.
I cannot take GLP-1’s due to anhedonia. I wonder if a low dose Orexin-A IN, would counteract this. Is there a low/starting dose that people are using?
A plausible mechanism
“The core experiments involved cross-docking the GLP-1R agonist, Danuglipron, with HCRTR2, and the established Orexin antagonist, Suvorexant, with GLP-1R. Both cross-docking pairs showed favourable binding affinities. The stability of both cross-docked complexes was further confirmed via Molecular dynamics simulation, which demonstrated low-deviation dynamics and persistent binding interactions. These results provide strong molecular and structural evidence that the GLP-1R and HCRTR2 signalling axes converge on common molecular hubs, offering an atomic-level mechanism for their functional interdependence and explaining potential polypharmacological effects of existing drugs. This is the first of its kind, comprehensive in silico framework demonstrating molecular convergence between GLP-1R and HCRTR2.”
Wait but isn’t sleep needed for all sorts of reasons? Repair, cognitive consolidation, immune clearance, insulin sensitivity, and many many more? I’d love to know HOW this is supposed to work without causing damage or incurring hidden tradeoffs? Can someone explain even a plausible road to sustainability?
The only plausible roads I can think of are either:
- Short term acting orexin agonists that you take in the morning and clear by late afternoon.
or - Take orexin agonist in the morning and orexin antagonists at night.
or - A treatment to improve orexin signalling in the brain to be more youthful.
Well there must be more to it than that because the folks with the mutation can go a lifetime on just 4 hours of sleep a night. There’s something here that doesn’t add up. Orexin must sit at the top of an untapped iceberg.
I interpreted your comment as asking how us regular folk can utilize exogenous orexin/agonists.
Orexin certainly is interesting. There are groups looking at orexin based treatments for ADHD, fatigue and more.
My only experience with anything that may upregulate it is modafinil and armodafinil, both which negatively impacted sleep. They’re something I’ll keep in my back pocket for extreme high level work.
1 Like
I’m more interested in understanding how it all works. If you catch my drift, your insomnia from the orexin agonist you tried might not be a problem if your body and brain didn’t miss out from anything in that lost sleep. I just don’t understand how such a thing can be even mechanistically plausible.
I think there is more going on in people who are genetically short sleepers. It isn’t as simple as taking more orexin. Modafinil did negatively impact sleep and health. Improving sleep through other means while using modafinil likely would offset most if not all negative effects.
1 Like
What more do you think is going on in genetic short sleepers? I can’t for the life of me figure it out. My sleep is excellent— both rem and deep and overall sleep duration and consolidation. But if anything I feel like I’ve inherited a long sleep mutation and I NEED a ton of sleep. And it’s becoming harder with age to keep full wakefulness and alertness throughout the day (though I suspect a big part of that is my environment being under stimulating to what I’ve been used to). But if I could take a drug that kept me super alert during the day without jitters and even lowered my need for sleep so I can wake up at 5:30 am and not suffer — neither psychologically nor physiologically — that would be amazing.
1 Like
I don’t know what more is going on but I suspect it is more than just more orexin production. Perhaps a more optimal metabolization, or slower aging of different neurons. Scientists really need to figure this one out and create an intervention to make everyone a “short sleeper”.
I believe that optimization of sleep is one of the best ways we can improve longevity.
I wrote about my theory here Sleep 2.0 – Understanding and Upregulating the Rejuvenating Aspects of Good Sleep
1 Like
A new podcast interview with the CEO of Alkermes, with lots of discussion on the news Orexin targeted drugs in clinical testing:
1 Like